Financial reports
10-Q
2024 Q1
Quarterly report
8 Feb 24
ARS
2023 FY
Annual report to shareholders
26 Jan 24
10-K
2023 FY
Annual report
22 Nov 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
10-Q
2023 Q2
Quarterly report
9 May 23
10-Q
2023 Q1
Quarterly report
8 Feb 23
ARS
2022 FY
Annual report to shareholders
7 Feb 23
10-K
2022 FY
Annual report
23 Nov 22
10-Q
2022 Q3
Quarterly report
8 Aug 22
10-Q
2022 Q2
Quarterly report
9 May 22
Current reports
8-K
Departure of Directors or Certain Officers
12 Mar 24
8-K
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
7 Feb 24
8-K
Departure of Directors or Certain Officers
26 Dec 23
8-K
Results of Operations and Financial Condition
20 Nov 23
8-K
Results of Operations and Financial Condition
7 Aug 23
8-K
Regulation FD Disclosure
7 Jun 23
8-K
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
8 May 23
8-K
Non-Dilutive and Strengthens Balance Sheet
27 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
7 Mar 23
Registration and prospectus
S-3
Shelf registration
22 Nov 23
POSASR
Automatic shelf registration (post-effective amendment)
22 Nov 23
S-8
Registration of securities for employees
8 Aug 23
424B5
Prospectus supplement for primary offering
26 Aug 22
S-8
Registration of securities for employees
9 May 22
S-3ASR
Automatic shelf registration
9 Aug 21
S-8
Registration of securities for employees
10 May 21
S-8
Registration of securities for employees
10 May 19
S-8
Registration of securities for employees
10 May 19
S-8
Registration of securities for employees
11 Dec 17
Proxies
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
DEFA14A
Additional proxy soliciting materials
20 Jan 23
DEF 14A
Definitive proxy
20 Jan 23
DEFA14A
Additional proxy soliciting materials
21 Jan 22
DEF 14A
Definitive proxy
21 Jan 22
DEFR14A
Revised proxy
28 Jan 21
DEF 14A
Definitive proxy
21 Jan 21
DEFA14A
Additional proxy soliciting materials
21 Jan 21
DEFA14A
Additional proxy soliciting materials
17 Jan 20
Other
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
27 Nov 23
CT ORDER
Confidential treatment order
17 Feb 16
CT ORDER
Confidential treatment order
16 Mar 15
CT ORDER
Confidential treatment order
28 Jun 13
CT ORDER
Confidential treatment order
21 Mar 13
EFFECT
Notice of effectiveness
20 Mar 13
CORRESP
Correspondence with SEC
18 Mar 13
CORRESP
Correspondence with SEC
18 Mar 13